1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
The synthesis and kinase inhibitory activity of a series of novel 1,7-annulated indolocarbazoles 6 and 16 is described. These compounds exhibited potent inhibitory activity against cyclin-dependent kinase 4 and good antiproliferative activity in a human colon carcinoma cell line.
Al-awar
Rima S
RS
Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. rima@lilly.com
Ray
James E
JE
Hecker
Kyle A
KA
Huang
Jianping
J
Waid
Philip P
PP
Shih
Chuan
C
Brooks
Harold B
HB
Spencer
Charles D
CD
Watkins
Scott A
SA
Patel
Bharvin R
BR
Stamm
Nancy B
NB
Ogg
Catherine A
CA
Schultz
Richard M
RM
Considine
Eileen L
EL
Faul
Margaret M
MM
Sullivan
Kevin A
KA
Kolis
Stanley P
SP
Grutsch
John L
JL
Joseph
Sajan
S
D002227:Carbazoles / Q000737:chemistry* / Q000494:pharmacology; D019938:Cyclin D1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D051358:Cyclin-Dependent Kinase 4; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007211:Indoles / Q000737:chemistry* / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism
D002227:Carbazoles; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D019938:Cyclin D1; D051358:Cyclin-Dependent Kinase 4; D018844:Cyclin-Dependent Kinases